首页> 外文期刊>Experimental and therapeutic medicine >Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis
【24h】

Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis

机译:靛蓝自然对葡聚糖硫酸钠诱导的溃疡性结肠炎大鼠结肠粘膜损伤和炎症的影响

获取原文
获取原文并翻译 | 示例
           

摘要

The effects of indigo naturalis (IN), which is a traditional Chinese herbal formulation, have been clinically demonstrated in treating refractory ulcerative colitis (UC). The present study aimed to verify the effects and mechanisms of IN in experimental UC rats. A total of 48 male Sprague-Dawley rats were randomly divided into six groups: Chow, model, high-dose IN, medium-dose IN, low-dose IN and mesalazine (a bowel-specific aminosalicylate drug) groups. The models were administered 3.5% dextran sodium sulphate solution for 7 days. The treatment groups were administered IN or mesalazine and then sacrificed and sampled on day 8. Disease activity index (DAI), histological damage score (HDS) and myeloperoxidase (MPO) activity were used to evaluate the severity of UC. Colon and serum cytokines were detected using liquid-phase chip technology and the expression of occludin protein in colonic mucosa was assessed by immunohistochemistry and western blot analysis. The results indicated that the oral administration of IN may reduce DAI, HDS and MPO activity. IN also reduced the expression of inflammatory cytokines and increased the expression of colonic mucosal repair-related cytokines and occludin protein. These results highlight the potential of IN as a therapeutic agent for treating UC through its action of inflammation control and colonic mucosal damage repair.
机译:在治疗难治性溃疡性结肠炎(UC)中,Indigo Naturalis(In)的影响已在治疗难治性溃疡性结肠炎(UC)方面已经证明。本研究旨在验证实验性UC大鼠中的效果和机制。共有48只雄性Sprague-Dawley大鼠随机分为六组:食物,模型,高剂量,中剂量,低剂量,和胚轴(肠特异性氨基水溶生药物)组。将模型施用3.5%葡聚糖硫酸钠溶液7天。施用处理基团或咪嗪,然后在第8天中处死和取样。疾病活性指数(DAI),组织学伤害评分(HDS)和髓氧化酶(MPO)活性用于评估UC的严重程度。使用液相芯片技术检测结肠和血清细胞因子,通过免疫组织化学和蛋白质印迹分析评估结肠粘膜中瘤粘土蛋白的表达。结果表明,口服施用可以减少DAI,HDS和MPO活动。还减少了炎性细胞因子的表达并增加了结肠粘膜修复相关细胞因子和occludin蛋白的表达。这些结果突出了通过其炎症控制和结肠粘膜损伤修复的作用来治疗UC的治疗剂的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号